Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)

NCT00087022 is registered in ClinicalTrials.gov with Heidelberg Pharma AG as lead sponsor.

NCT NCT00087022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00087022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Lead sponsor
Heidelberg Pharma AG
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2004
Completion date
October 31, 2012
Enrollment
864 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer